IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Childhood Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase Chronic Myelogenous Leukemia Relapsing Chronic Myelogenous Leukemia | Drug: omacetaxine mepesuccinate Other: pharmacological study Other: laboratory biomarker analysis | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase I and Pilot Study of Subcutaneous Homoharringtonine in Chronic Myelogenous Leukemia |
- Maximum-tolerated dose (MTD) of homoharringtonine as assessed by the National Cancer Institute (NCI) Common Terminology Criteria (CTC) [ Time Frame: 14 days ]
- Complete hematologic remission (CHR) defined as at least 4 weeks of bone marrow (less than 5% blasts) and peripheral blood with WBC < 10 x 10^9/L and no peripheral blasts, promyelocytes, or myelocytes [ Time Frame: Up to 6 years ]Using a Bayesian approach.
| Enrollment: | 50 |
| Study Start Date: | November 1999 |
| Primary Completion Date: | September 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment (omacetaxine mepesuccinate)
Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses. Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity. |
Drug: omacetaxine mepesuccinate
Given IV or SC
Other Names:
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: laboratory biomarker analysis
Correlative studies
|
Detailed Description:
OBJECTIVES:
I. Determine the maximum tolerated dose of homoharringtonine in patients with transformed phases of chronic myelogenous leukemia (CML). (Phase I completed as of 2/11/2004.) II. Determine the toxicity profile of this drug in these patients. III. Determine the response duration in patients with chronic phase CML treated with this drug.
IV. Compare the pharmacokinetics of this drug administered as a continuous infusion vs subcutaneously in these patients.
OUTLINE: This is a pilot, dose-escalation study. (Phase I completed as of 2/11/2004.)
Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.
Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of homoharringtonine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 25-30 patients with chronic phase chronic myelogenous leukemia receives remission induction and maintenance therapy as above at the MTD. (Phase I completed as of 2/11/2004.)
Patients are followed every 3 months.
PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 12 Years and older (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Diagnosis of chronic phase chronic myelogenous leukemia (CML), as defined by the following:
- Less than 15% blasts in the peripheral blood (PB) or bone marrow (BM)
- Less than 20% basophils in the PB or BM
- Platelet count > 100,000/mm^3 (unless related to therapy)
- Absence of clonal evolution*
- Philadelphia chromosome- OR BCR/ABL-positive disease by cytogenetics, fluorescence in situ hybridization, or polymerase chain reaction
-
Failed prior therapy with imatinib mesylate, as defined by any of the following:
- Failed to achieve or have lost a complete hematologic remission after 3 months of therapy
- Failed to achieve or have lost at least a minimal cytogenetic response after 6 months of therapy
- Failed to achieve or have lost a major or complete cytogenetic response after 12 months of therapy
- Unable to tolerate imatinib mesylate despite adequate dose adjustment
-
Failed no more than 2 prior treatment regimens (in addition to imatinib mesylate)
- Treatment with hydroxyurea is not considered one regimen
- Ineligible for known regimens or protocols of higher efficacy or priority
- Performance status - Zubrod 0-2
- At least 2 months
- Bilirubin no greater than 2.0 mg/dL
- Creatinine less than 2.0 mg/dL
- No New York Heart Association class III or IV heart disease
- Not pregnant or nursing
- Fertile patients must use effective contraception
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00006364
| United States, Texas | |
| M D Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: | Jorge Cortes | M.D. Anderson Cancer Center |
More Information
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00006364 History of Changes |
| Other Study ID Numbers: |
NCI-2012-02360 ID 99-032 N01CM17003 ( U.S. NIH Grant/Contract ) CDR0000068237 ( Registry Identifier: PDQ (Physician Data Query) ) |
| Study First Received: | October 4, 2000 |
| Last Updated: | January 22, 2013 |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid, Chronic-Phase Neoplasms by Histologic Type Neoplasms Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases |
Homoharringtonine Harringtonines Antineoplastic Agents, Phytogenic Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |
ClinicalTrials.gov processed this record on July 21, 2017